Nippon Universal Of Japan To Add Sales Staff For Parent Zydus Generics
This article was originally published in PharmAsia News
Japan's Nippon Universal Pharmaceutical, a subsidiary of India's Zydus, plans an expansion within Japan, increasing its medical representative staff from 30 to 50. Although Zydus specializes in generics, the new staff members are to handle new drugs that result from a partnership between Zydus and Eli Lilly of the United States. Nippon Universal plans to introduce as many as six generics to have a portfolio of more than 30 drugs by the end of this year. Zydus also is considering handling generics made by other drug makers in addition to its own line. (Click here for more - a subscription may be required
You may also be interested in...
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.
Sun Pharma and its US Taro subsidiary have further criticized a recent CMS policy proposal that would see Medicare Part B drugs approved under the US hybrid 505(b)(2) pathway reimbursed at a lower rate applicable to multiple source products.
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.